Congress trades

NeoGenomics, Inc. (NEO)

Medical Diagnostics & Research, listed on NASDAQ.

5 Congress tradeslast filed Sep 10, 2026

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

EarningsQ3 FY2026 · reported Oct 28, 2026

NeoGenomics beat on EPS, and revenue came in line.

$0.07 a share against a $0.06 consensus. Revenue $209M against $207M.

EPS

Reported$0.07
Consensus$0.06

Revenue

Reported$209M
Consensus$207M

Beat 5In line 1

Next report Feb 16, 2027. Consensus $0.07 a share.

Every quarter

Money managers13F filings for Sep 30, 2026

98

institutions reported NeoGenomics shares in 13F filings for Sep 30, 2026. BlackRock, Inc. held the largest stake, $368.9M.

The largest holders

BlackRock, Inc.$368.9M
Vanguard Portfolio Management LLC$143.0M
First Trust Advisors LP$136.3M
Every holder

CongressSTOCK Act disclosures to the House and Senate

5 Congress disclosures shown, from 3 members.

30dMedian delayof the 45 day limit
4 buys · 1 sellPurchases and sales in the disclosures shown

2 members of Congress report a position in NEO, by our estimate. Who holds it

Every Congress trade in NEOEvery disclosure
Companyfrom the company's filings and listing, as of Nov 15, 2026

About NeoGenomics, Inc.

Exchange
NASDAQ
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Chief executive
Anthony Zook
Employees
2,500
Listed since
Mar 16, 2004
Market value
$2.1B
Price to earnings (12 mo)
-
Net income per share, as reported (12 mo)
-$0.25
Dividend yield
-

www.neogenomics.com

Earnings6 reported quarters · next on Feb 16, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Oct 28, 2026$0.07$0.06$209.3M$206.7MEPS beatRevenue in line
Q2 FY2026reported Jul 28, 2026$0.05$0.03$201.7M$196.9MEPS beatRevenue beat
Q1 FY2026reported Apr 28, 2026$0.01$0.01$186.7M$184.5MEPS beatRevenue in line
Q4 FY2025reported Feb 17, 2026$0.06$0.04$190.2M$188.5MEPS beatRevenue in line
Q3 FY2025reported Oct 28, 2025$0.03$0.02$187.8M$188.2MEPS beatRevenue in line
Q2 FY2025reported Jul 29, 2025$0.03$0.03$181.3M$183.9MEPS in lineRevenue in line

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

No earnings call briefs on NEO yet. Briefs from every company we cover.

Analysts

Analyst ratings and price targets

Past year Each firm's latest target, newest first

Each firm's latest price target on NEO, newest first
FirmRatingTargetActionDate
JefferiesNot stated$21Target set
NeedhamBuy$22Target set
BTIGBuy$28Target set
Craig-HallumNot stated$19Target set
Piper SandlerOverweight$13Target set

Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice.

3 other firms rated NEO in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 16, 2026.

Proxy statementas filed for fiscal 2025 · proxy filed Apr 6, 2026

Executive pay

Tony Zook’s pay as CEO came to $9.1M for fiscal 2025.
ExecutiveSalaryStock awardsOtherTotal
Tony ZookDirector and Chief Executive Officer$602K$4.0M$4.5M$9.1M
Warren StoneChief Commercial Officer$630K$2.2M$2.2M$5.1M
Jeffrey ShermanChief Financial Officer$604K$2.3M$1.8M$4.7M
Alicia OlivoExecutive Vice President, General Counsel and Business Development$523K$1.5M$1.0M$3.0M
Gary PassmanChief Culture Officer$448K$1.1M$870K$2.4M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 2 executives who have since left the company are named in that filing and not shown here. Read the filing

13F filings13F positions as of Sep 30, 2026

Institutional holders

HolderValueSharesShares vs prior qtr
BlackRock, Inc.$368.9M20,091,857-3.7%
Vanguard Portfolio Management LLC$143.0M7,788,960-3.4%
First Trust Advisors LP$136.3M7,424,916-26.6%
Vanguard Capital Management LLC$105.5M5,744,064-0.3%
State Street Corp$98.2M5,346,829-0.3%
Geode Capital Management, LLC$62.7M3,416,439-0.3%
Loomis Sayles & Co. L.P.$58.9M3,209,567+26.5%
Gw&K Investment Management, LLC$51.9M2,827,884+32.8%
Dimensional Fund Advisors LP$47.6M2,590,055+7.9%
Arrowstreet Capital, Limited Partnership$42.8M2,333,082-2.5%
Invesco Ltd.$38.3M2,083,853+247.3%
Morgan Stanley$30.4M1,656,710-12.7%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Sep 30, 2026. Percentages of shares outstanding are left out: the share count they were worked out against puts this company's holders past 100% between them. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

STOCK Act5 disclosures of 5 on record · median 30d of the 45 allowed

Congress trades in NEO

Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.

MemberTypeActionAmount disclosedSince the tradeTrade dateDisclosedDelay
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000-3.3% since the tradeEstimated entry price $16.57, close on Fri Aug 7Current price $16.02, close on Fri Nov 13Aug 7, 2026Sep 10, 202634d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000+100.3% since the tradeEstimated entry price $8.00, close on Wed May 7, 2025Current price $16.02, close on Fri Nov 13May 7, 2025Jun 6, 202530d
Dwight EvansStockSale$1,001 - $15,000+23.7% since the saleEstimated exit price $12.95, close on Wed Mar 30, 2022Current price $16.02, close on Fri Nov 13Mar 30, 2022Apr 25, 202226d
Deborah K. RossSpouseStockPurchase$15,001 - $50,000-53.1% since the tradeEstimated entry price $34.15, close on Thu Dec 30, 2021Current price $16.02, close on Fri Nov 13Dec 30, 2021Jan 8, 20229d
Dwight EvansStockPurchase$1,001 - $15,000-45.7% since the tradeEstimated entry price $29.48, close on Mon Mar 2, 2020Current price $16.02, close on Fri Nov 13Mar 2, 2020Apr 23, 202052d

Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in NEO filterable by party, chamber, type and account.

STOCK Act2 members · estimate, as of Nov 15, 2026

Members of Congress reporting a position

2 members report a position (estimated).
MemberParty, chamberEstimated positionShare of their portfolio
Gilbert Ray Cisneros, Jr.Democrat · House$15,001 - $50,0000.1%
Deborah K. RossDemocrat · House$1,001 - $15,0000.8%

The largest estimated position is in the $15,001 - $50,000 band. Estimate, as of Nov 15, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, marked to the latest close we hold. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.

Data as of Nov 16, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on NEO show and how current they are.

Which members of Congress have traded NEO?

Gilbert Ray Cisneros, Jr., Dwight Evans and Deborah K. Ross disclosed NEO transactions in the filings shown here.

Which members of Congress hold NEO?

2 members of Congress report a position in NEO in the estimate we hold as of Nov 15, 2026. The estimated positions belong to Gilbert Ray Cisneros, Jr. and Deborah K. Ross. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.

How quickly are NEO trades disclosed?

Congressional disclosures took a median of 30 days, against the 45 the STOCK Act allows.

Related companies

traded by the same members

See every company we track